CD38 and cancer: Interestingly, they found that ATRA significantly increased the expression of CD38 in cancer cell lines with low expression of this marker, thus producing a synergistic effect with CAR-T cells or daratumumab and expanding the possibility of considering CD38 as an efficient target in a wider type of lymphoid malignancies as well.